Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

CUSIP: 84833T103

Q4 2022 13F Holders as of 31 Dec 2022

Security type / class
Equity / Common Stock, par value $0.001 per share
Total 13F shares
14,222,474
Total 13F value
$24,601,496
Holder snapshot 6 visible 7 signals
Share change
-5,647,507
Put/Call ratio
35%
SEC-reported price per share
$1.73
Number of holders
57
Value change
-$11,539,486
Number of buys
24
Open additional details 1 more signal available
Number of sells
36
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
55,705,828

Security key

84833T103

Report period

Q4 2022

Institutions

57

Top holders

10

SPRO full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2023 Previous quarter: Q3 2022 Spero Therapeutics, Inc. SEC filings Spero Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Aquilo Capital Management...
Disclosed value leader
Aquilo Capital Management...
Comparable rows
15/15
Latest evidence
30 Sep 2022
13F 3/4/5 Lead comparable stake: 6.1% Showing 1-6 of 15 holder rows.

Quick read

Aquilo Capital Management, LLC leads the comparable SEC ownership view at 6.1%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Aquilo Capital Management, LLC's linked filing trail.
Comparable ownership Top 5
Aquilo Capital Management, LLC 6.1%
AWM Investment Company, Inc. 4.1%
BVF INC/IL 3.5%
Anson Funds Management LP 2.6%
Atlas Venture Associates IX, LLC 2.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Aquilo Capital Management, LLC
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
6.1%
$6,806,000
3,403,210 shares
 — 30 Sep 2022
AWM Investment Company, Inc.
13F
Company
13F
4.1%
$4,601,000
2,300,400 shares
 — 30 Sep 2022
BVF INC/IL
13F
Company
13F
3.5%
$3,859,000
1,929,376 shares
 — 30 Sep 2022
Anson Funds Management LP
13F
Company
13F
2.6%
$2,948,000
1,473,872 shares
 — 30 Sep 2022
Atlas Venture Associates IX, LLC
13F
Company
13F
2.5%
$2,754,000
1,376,968 shares
 — 30 Sep 2022
VANGUARD GROUP INC
13F
Company
13F
1.9%
$2,107,000
1,053,723 shares
 — 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
57
Shares
14,222,474
Rows available
57
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
61
Q4 2022 holders
57
Holder diff
-4
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .